A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy

Trial Profile

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Docetaxel; Paclitaxel; Vinflunine
  • Indications Bladder cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms IMvigor 211
  • Sponsors Roche
  • Most Recent Events

    • 21 Jul 2017 According to a Roche media release, data from this trial were presented at EACR-AACR-SIC Special Conference 2017.
    • 21 Jul 2017 According to a Roche media release, the CHMP adopted a positive opinion for the use of TECENTRIQ as a monotherapy. This positive opinion is based on results from the IMvigor211 study and cohorts 1 and 2 of the IMvigor210 study.
    • 10 May 2017 According to a Genentech media release, this is a randomized pivotal study designed to support full approval globally and to serve as the confirmatory study to convert the accelerated approval to full approval in the U.S.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top